

## 2019-20 National Advisory Committee on Immunization (NACI) Workplan

### Preamble:

The following represents the National Advisory Committee on Immunization's planned work for the 2019-2020 fiscal year (April 2019 to March 2020). These projects will not necessarily be completed within the fiscal year. This work plan may be reassessed based on emerging public health needs. Triggers for the activation of Working Groups (WGs) and the development of new NACI guidance documents, or the adoption of new priorities may include the following:

new vaccine or new indication, new recommendation by an authoritative Canadian body (government or professional organization), provincial or territorial (P/T) programmatic concerns, recommendation adopted by reputable international organizations, new safety signal detected, vaccine supply issue, anticipated public health emergency, changes in disease epidemiology, Canadian Immunization Guide (CIG) chapter review, publication of key trials, internal inconsistency, update to product monograph.

Initiative	Issue(s)	Triggers	Expected date of completion*
<b>Ebola Virus Disease</b>	Interim pre-market guidance on domestic use of stockpiled investigational vaccine for ring vaccination strategy in event of imported cases, post-market guidance to follow in later years	New vaccine	Q2 2019 for interim guidance
<b>Hepatitis A</b>	Consider a universal hepatitis A vaccine schedule, including 1-dose option	Recommendation adoption by reputable organization	2021
<b>Measles, Mumps, Rubella (MMR)</b>	Consider additional dose of mumps-containing vaccine in outbreaks	Changes in disease epidemiology	2019-20
	Full CIG chapter update for Measles, Mumps and Rubella due	CIG chapter reviews due	2019-20
<b>Pertussis</b>	Optimal timing of adult and adolescent Tdap boosters, including Td intervals	P/T programmatic concerns	2020
<b>Pneumococcal</b>	Evaluation of preferential PCV13 recommendation for routine infant programs	Recommendation adoption by reputable organization	2020
<b>Rabies</b>	Updated guidance on rabies vaccine PrEP and PEP in context of new guidance from WHO	Recommendation adoption by reputable organization	2020
	Full CIG chapter review due	CIG chapter review due	2020
<b>Respiratory Syncytial Virus (RSV)</b>	Review/update NACI guidance on Palivizumab	Recommendation adoption by reputable organization	2019-20
	CIG - chapter creation		2019-20
<b>Seasonal Influenza</b>	Seasonal influenza	New vaccine	2020-21
	New Products: quadrivalent influenza vaccines	New vaccine	2020-21 (dependant on NOC)
	Repeated vaccination	P/T programmatic concerns	2020
<b>CIG: Part 1 (Key immunization information)</b>	Routine chapter updates (6): Immunization in Canada, Benefits of Immunization, National Guidelines for Immunization Practices, Communicating Effectively about Immunization, Principles of Vaccine Interchangeability, Blood Products, Human Immune Globulin and Timing of Immunization	CIG chapter reviews due	2019-20
<b>CIG : Part 2: Vaccine Safety</b>	Routine Chapter updates (3)	CIG chapter reviews overdue	2019-20
<b>CIG: Part 3: Special Populations</b>	Routine chapter updates (6): Immunization of Adults, Immunization of Persons with Inadequate Immunization Records, Immunization of Infants Born Prematurely, Immunization of Patients in Healthcare Institutions, Immunization of Persons New to Canada, Immunization of Workers	CIG chapter reviews overdue	2019-20

## 2019-20 National Advisory Committee on Immunization (NACI) Workplan

Initiative	Issue(s)	Triggers	Expected date of completion*
<b>CIG: Part 4: Active Vaccines</b>	Routine chapter updates (12): BCG, Diphtheria, Hib, MMR, Polio, Rabies, Smallpox, Tetanus, YF, JE	CIG chapter reviews due and some overdue	2019-20
<b>Ethics, Equity, Feasibility, Acceptability (EEFA)</b>	Incorporation into NACI process: EEFA	Recommendation adoption by reputable organization	2019
<b>NACI economics framework</b>	Incorporation into NACI process: economics framework	Recommendation adoption by reputable organization	2020
<b>Economic guidelines</b>	Incorporation into NACI process: economic guidelines	Recommendation adoption by reputable organization	2021

*\*Please note that this workplan is evergreen. As new products and indications are authorized or new information becomes available, workplan items may be added for consideration and priorities may change.*

### Abbreviations:

<b>NACI</b>	National Advisory Committee on Immunization
<b>BCG</b>	Bacillus Calmette–Guérin
<b>CATMAT</b>	Committee to Advise on Tropical Medicine and Travel
<b>CCDR</b>	Canada Communicable Disease Report
<b>CIC</b>	Canadian Immunization Committee
<b>CIG</b>	Canadian Immunization Guide
<b>CPS</b>	Canadian Paediatric Society
<b>EEFA</b>	Ethics, Equity, Feasibility, Acceptability
<b>FY</b>	Fiscal year (April 1 - March 31)
<b>Hib</b>	Haemophilus influenzae type b
<b>JE</b>	Japanese encephalitis
<b>NoC</b>	Notice of compliance
<b>PCV13</b>	Pneumococcal conjugate vaccine
<b>PEP</b>	Post-exposure prophylaxis
<b>PrEP</b>	Pre-exposure prophylaxis
<b>P/Ts</b>	Provinces and territories
<b>QIV</b>	Quadrivalent influenza vaccine
<b>SOGC</b>	Society of Obstetricians and Surgeons of Canada
<b>Td</b>	Tetanus and diphtheria vaccine
<b>Tdap</b>	Tetanus, diphtheria and pertussis vaccine
<b>TIV</b>	Trivalent influenza vaccine
<b>TOR</b>	Terms of reference
<b>WG</b>	Working group
<b>WHO</b>	World Health Organization
<b>YF</b>	Yellow fever